Amgen (AMGN) Equity Average (2009 - 2026)

Amgen has reported Equity Average for 18 years, with the latest figure at $8.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 47.7% year-over-year to $8.9 billion; the trailing twelve-month figure through Mar 2026 stood at $8.9 billion (up 47.7% YoY), and the FY2025 full-year result was $7.3 billion, up 20.03% from the prior year.
• Equity Average for Q1 2026 stood at $8.9 billion, down from $9.1 billion in the prior quarter.
• The five-year high for Equity Average was $9.1 billion in Q4 2025, with the low at $1.7 billion in Q2 2022.
• Average Equity Average over 5 years is $5.9 billion, with a median of $6.1 billion recorded in 2023.
• Year-over-year, Equity Average tumbled 81.03% in 2022 and soared 263.69% in 2023.
• Tracing AMGN's Equity Average over 5 years: stood at $3.7 billion in 2022, then surged by 89.88% to $6.9 billion in 2023, then retreated by 3.49% to $6.7 billion in 2024, then surged by 36.35% to $9.1 billion in 2025, then fell by 2.35% to $8.9 billion in 2026.
• The last three Equity Average figures came in at $8.9 billion (Q1 2026), $9.1 billion (Q4 2025), and $8.5 billion (Q3 2025), per Business Quant data.

Peer Comparison